Revance Therapeutics, Inc. (RVNC) stock experienced sudden downfall – Reasons behind it!
Revance Therapeutics, Inc. (RVNC) has experienced a decline of 33.07% in the aftermarket because the company provided a Regulatory Update on DaxibotulinumtoxinA. However, the last trading session concluded at $22.71 with an increase of 0.66%. Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines On 15th October 2021, […]
Needham maintains Revance Therapeutics [RVNC] at Buy rating with a $45 price target
Needham maintained its Revance Therapeutics [RVNC] rating to the equivalent of Buy but changed the price target to $45.0 from $42, in a research note dated 2021-01-08. That figure represents around a 52.08% premium from where the company’s shares closed on Thursday. Meanwhile, Goldman had lowered its rating on RVNC to “Neutral” from the earlier […]